Skip to content
My WebMD Sign In, Sign Up

Breast Cancer Health Center

Font Size

Genetics of Breast and Ovarian Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Low- and Moderate-Penetrance Genes Associated With Breast and / or Ovarian Cancer

Table 8. High-probability Breast Cancer Susceptibility Loci Identified Through Genome-Wide Association Studies

Putative Gene(s)ChromosomeSNPStudy CitationaOdds Ratio (OR) (95% Confidence Interval [CI])bComments
ER- = estrogen receptor–negative; ER+ = estrogen receptor–positive; PR- = progesterone receptor–negative; PR+ = progesterone receptor–positive; SNP = single nucleotide polymorphism; triple-negative = ER-/PR-/HER2/neu-.
a Initial study that demonstrated genome-wide significance for each locus.
b All associations observed in the general population, unless otherwise indicated; when relevant, if association was also observed inBRCA1orBRCA2mutation carriers, it is indicated.
c OR for best tagSNP was used[109]as a surrogate for published SNP.
Intergenic /NOTCH21p11.2rs11249433[89]1.08 (1.02–1.15)[109]Stronger in ER+, low-grade[109]; also inBRCA2[119]
ERBB22q34rs13393577[120]1.53 (1.37–1.70)[120]Identified in Korean subjects[120]
Intergenic2q35rs13387042[107]1.21 (1.14–1.29)[109]Stronger in bilateral and lobular[116]; also inBRCA1andBRCA2[121]
SLC4A7, NEK103p24rs4973768[115]1.16 (1.10–1.24)[109]Also inBRCA2[121]
MRPS305p12rs10941679[114]1.11c(1.04–1.19)[109]Strongest in PR+, low-grade[122]; also inBRCA2[121]
TERT-/CLPTM15p15rs10069690[117]1.25 (1.16–1.34)[117]Strongest in triple-negative[117]
MAP3K1 5q11.2rs889312[106]1.22 (1.14–1.30)[109]Stronger in ER+[109]; also inBRCA2[121]
RNF1466q22rs2180341[110]1.24 (1.13–1.36)[123]Stronger in Ashkenazi Jews[123]
ESR16q25.1rs2046210[111]1.15c(1.08–1.22)[109]Also inBRCA1[119]
TAB26q25.1rs9485372[124]0.90 (0.87–0.92)[124]Identified in Chinese subjects[124]
Intergenic7q32.3rs2048672[125]1.11 (1.05–1.17)[125]Identified in East Asian subjects[125]
Intergenic/MYC8q24.21rs13281615[106]1.14 (1.07–1.21)[109]Stronger in ER+[109]
CDKN2A, CDKN2B9p21rs1011970[109]1.09 (1.04–1.14)[109]Stronger in ER+[109]; also inBRCA2[126]
Intergenic9q31.2rs865686[127]0.89(0.85–0.92)[127]Also inBRCA2[126]
ANKRD16, FBXO1810p15.1rs2380205[109]0.94 (0.91–0.98)[109] 
ZNF365 10q21.2rs10995190[109]0.86 (0.82–0.91)[109]Stronger in ER+ in general population[109]; also inBRCA2[128]
ZMIZ110q22.3rs704010[109]1.07 (1.03–1.11)[109] 
FGFR2 10q26.13rs2981582[106]1.43 (1.35–1.53)[109]Strongest for ER+, low-grade[116]; also inBRCA2[121]
LSP111p15.5rs3817198[106]1.12 (1.05–1.19)[109]Also inBRCA2[121]
Intergenic11q13rs614367[109]1.15 (1.10–1.20)[109]Restricted to ER+ tumors; strongest for ER+/PR+[109]
BARX211q24.3rs7107217[124]1.08 (1.05–1.11)[124]Identified in Chinese subjects[124]
PTHLH12p11rs10771399[129]0.85 (0.83–0.88)[129]Also inBRCA1[126]
Intergenic12q24rs1292011[129]0.92 (0.91–0.94)[129]Restricted to ER+[129]; also inBRCA2[126]
RAD51B14q24.1rs999737[89]0.89 (0.83–0.95)[109]Associated with all subtypes, including triple-negative[90]; also inBRCA2[126]
TOX316q12.1rs3803662[106]1.30 (1.22–1.39)[109]Stronger in ER+[116]; also inBRCA1andBRCA2[121]
BABAM119p13.1rs8170[118]1.26 (1.17–1.35)[130]Restricted to triple-negative in general population[118]; also inBRCA1[130]
NRIP121q21rs2823093[129]0.94 (0.92–0.96)[129]Restricted to ER+[129]

Table 9. High-probability Ovarian Cancer Susceptibility Loci Identified Through Genome-Wide Association Studies

Putative Gene(s)ChromosomeSNPStudy CitationOdds Ratio (95% Confidence Interval)Comment
SNP = single nucleotide polymorphism.
HOXD12q31.1rs2072590[131]1.16 (1.12–1.21)Stronger in serous cancers
TIPARP3q25.31rs2665390[131]1.19 (1.11–1.27) 
Intergenic/MYC,THEM758q24.21rs10088218[131]0.84 (0.80–0.89) 
BNC29p22.2rs3814113[132]0.82 (0.79–0.86)Stronger in serous cancers; also inBRCA1andBRCA2[133]
SKAP117q21.32rs9303542[131]1.11 (1.06–1.16) 
BABAM119p13.11rs8170[134]1.18 (1.12–1.25)Serous cancers only
ANKLE119p13.11rs2363956[134]1.16 (1.11–1.21) 

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
Breast Cancer Treatments Improving
Resolved To Quit Smoking
Woman getting mammogram
Screening Tests for Women
ovarian cancer overview slideshow
serious woman
what is your cancer risk
10 Ways to Revitalize Slideshow